GlassScriptPhysician profile
Joseph Haddad
NPI 1427672203
$785.49
in general payments reported to CMS, 2019-2025
18 companies · $605 in 2025
The $605 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $48.26 · 2023: $132 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $737.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $140.28 | 2025 | Omnipod |
| Medtronic, INC. | $131.81 | 2023 | Minimed 780g |
| Novo Nordisk INC | $101.51 | 2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.62 | 2025 | Jardiance |
| Horizon Therapeutics Plc | $48.26 | 2022 | |
| Sequel Med Tech, LLC | $41.22 | 2025 | Twiist |
| Azurity Pharmaceuticals, INC. | $32.09 | 2025 | Triptodur |
| Sanofi-Aventis U.S. LLC | $31.81 | 2025 | |
| Corcept Therapeutics | $28.66 | 2025 | Korlym |
| Radius Health, INC. | $25.39 | 2025 | Tymlos |
| Neurocrine Biosciences, INC. | $23.03 | 2025 | |
| Eton Pharmaceuticals, INC. | $22.67 | 2025 | Increlex, Alkindi, Khindivi |
| Mannkind Corporation | $21.59 | 2025 | |
| Dexcom, INC. | $21.50 | 2025 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $19.74 | 2025 | Yorvipath |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $16.59 | 2025 | Xyosted |
| Lilly USA, LLC | $14.83 | 2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $13.89 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Haddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.